Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04476901 · ClinicalTrials.gov registry record · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
A Phase 2 study of Non-ischemic Dilated Cardiomyopathy, sponsored by Joshua M Hare.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 4
- Study locations
NCT04476901 is a Phase 2 study of Non-ischemic Dilated Cardiomyopathy that is actively recruiting participants, run by Joshua M Hare. The registered enrollment target is 136 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT04476901, a Phase 2 study of Non-ischemic Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Joshua M Hare.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL allogeneic human mesenchymal stem cells (hMSCs)
Study Locations (4)
California
- Stanford University - Stanford
Florida
- University of Miami Miller School of Medicine - Miami
Kentucky
- University of Louisville - Louisville
Texas
- Texas Heart Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04476901
The ClinicalTrials.gov registry entry for NCT04476901 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua M Hare, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-ischemic Dilated Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04476901 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04476901 about?
NCT04476901 is a clinical study titled "Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy". The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.
What is the current status of trial NCT04476901?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2021-05-07. Estimated completion is 2025-12.
What conditions does trial NCT04476901 study?
This clinical trial studies the following conditions: Non-ischemic Dilated Cardiomyopathy.
What interventions are being tested in trial NCT04476901?
The interventions under investigation include: Placebo (OTHER), allogeneic human mesenchymal stem cells (hMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04476901?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04476901 being conducted?
This trial has 4 study locations across California, Florida, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.